PRMT5 and adrenal cortex carcinoma: Although PRT543 and JNJ-64619178(another PRMT5 inhibitor under early clinical investigation) had a favorable toxicity profile and showed preliminary evidence of antitumor activity in patients with advanced ACC, the observed efficacy was limited [45, 116].